Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Do Microglia in the Hypothalamus Drive Aging?
3 May 2013. Microglia have taken center stage in Alzheimer’s disease (AD) research recently. Not only have genetics studies pinpointed variants in the microglial receptor TREM2 as major risk factors for AD (see ARF related news story), but tuning down microglial cytokines has been shown to reduce plaque buildup (see ARF related news story), and a new network analysis links microglial dysfunction with AD pathology (see upcoming ARF Webinar). Could microglia also accelerate aging, the strongest risk factor for AD? In the May 1 Nature, Dongsheng Cai and scientists at the Albert Einstein College of Medicine, Bronx, New York, report that microglial inflammation in the hypothalamus of mice caused overall senescence, shortened lifespan, and weakened cognition. Conversely, quelling glial activation slowed aging and raised performance on cognitive tests. This study could have implications for the treatment of age-associated disorders, such neurodegeneration, cardiovascular disease, and diabetes, wrote the authors.

"This work places microglia at the epicenter of the aging process,” wrote Terrence Town, University of Southern California, Los Angeles, in an e-mail to Alzforum. "This neuroinflammatory pathway has obvious implications for AD,” he added.

Almond sized, the human hypothalamus releases hormones for growth, reproduction, and metabolism. Cai’s group previously showed that inflammation in the hypothalamus contributes to the development of obesity, glucose intolerance, and hypertension—all metabolic syndrome components associated with aging and Alzheimer's disease. These disorders came about upon activation of a central regulator of immunity—a proinflammatory transcription factor called nuclear factor κB (NF-κB), and its upstream IκB kinase-β (IKK-β (see Li et al., 2012; Zhang et al., 2008; and Purkayastha et al., 2011). NF-κB is elevated in the brains of those who died with AD (see Terai et al., 1996) and has been reported to exacerbate Aβ pathology under pathological conditions (see Chami et al., 2012). Cai and colleagues wondered if NF-κB signaling might be tied to aging.

To probe that question, co-first authors Guo Zhang, Juxue Li, Sudarshana Purkayastha, Yizhe Tang, and Hai Zhang first looked at how hypothalamic NF-κB activity changed over the mouse lifespan. They found little of the transcription factor in the hypothalamus of young mice, but it rose as the animals aged. The researchers then chronically activated NF-κB in the hypothalamus of middle- to old-age mice, using a lentiviral vector that carried IKK-β. This shortened lifespan reduced bone mass, wasted muscle, and left the animals with thinner skin. NF-κB activation also worsened cognitive performance on the Morris water maze. On the other hand, blocking hypothalamic NF-κB lengthened lifespan relative to controls, elevated performance on cognitive tests, and improved age-related biomarker profiles.

Microglia appeared to be initial players in this aging process. The number of microglia with activated NF-κB grew with age in the hypothalamus, and they overproduced inflammatory cytokines such as tumor necrosis factor-α. TNF-α is both induced by and activates NF-κB in a feed-forward loop. TNF-α also activates IKK-β. Nearby hypothalamic neurons later upped their own NF-κB and TNF-α production, implying that the microglial output led to inflammatory neuron changes.

Could reining in microglia control aging? When the researchers knocked out IKK-β in hypothalamic microglia of middle-aged mice, microglia numbers held steady with age, while TNF-α remained low. When they got older, these knockouts outperformed wild-type controls on the Morris water maze test and retained more muscle strength, bone mass, and skin thickness. Their maximum lifespan stretched to about 1,100 days, around 10 percent longer than the wild-type. Together, the results suggest that microglial IKK-β accelerates aging.

How does microglial NF-κB signaling reduce lifespan? Looking for the downstream effects, the researchers found that gonadotropin-releasing hormone (GnRH), which regulates sex hormones and reproduction, was diminished. Does its reduction accelerate aging? Levels of the hormone fell in the hypothalamus with age—a decline prevented by inhibition of IKK-β and NF-κB, and enhanced by their activation. GnRH replacement therapy seemed to turn back the clock. Both wild-type and IKK-β knockout mice injected subcutaneously with GnRH for up to eight weeks showed fewer signs of age and performed better on cognitive tests than untreated controls. This youthening may be related to neurogenesis, which declines with age. When injected into the hypothalamus of old mice, GnRH seemed to promote differentiation of new neurons—indicated by BrdU labeling. This is the first time GnRH has been tied to neurogenesis, Cai said. The new cells would have to be tested with appropriate markers to be sure it was true neurogenesis, wrote Gerd Kempermann, Center for Regenerative Therapies, Dresden, Germany, to Alzforum in an e-mail.

Treatments that target GnRH could translate to humans if scientists find a safe, efficacious method, said Cai. Such therapies might help prevent age-related disorders, including diabetes, cardiovascular disease, and neurodegenerative disease. “People tend to think about aging as a passive, chaotic deterioration of tissues,” Cai told Alzforum. “We provide a new view—it includes a brain-controlled process.”

The suggestion that the aging process is driven by the integration of immune and hormonal responses is a new paradigm, wrote Dana Gabuzda and Bruce Yankner of Harvard Medical School, Boston, in an accompanying editorial. It “raises the intriguing possibility that hypothalamic regulation could be therapeutically manipulated to have broad effects on the aging process.”

In addition to the reported effects on aging, the hypothalamus coordinates energy metabolism and stress responses, wrote Mark Mattson, National Institute on Aging, Baltimore, Maryland, to Alzforum in an e-mail (see full comment below). It would be interesting to explore how these pathways influence each other, he added. Metabolic syndrome and stress are both potential risk factors for AD (see ARF related news series).

This study provides some of the first evidence in a mammalian system that one entity centrally regulates the aging process. “I think the brain is going to turn out to be more important than any other tissue for mammalian aging,” said Leonard Guarente, Massachusetts Institute of Technology, Cambridge. He and colleagues recently reported that length of circadian periods, which are regulated by a portion of the hypothalamus, determine lifespan in mice (see Libert et al., 2012). “Maybe we’ve underestimated the importance of the hypothalamus,” he said.—Gwyneth Dickey Zakaib.

References:
Zhang G, Li J, Purkayastha S, Tang Y, Zhang H, Yin Y, Li B, Liu G, Cai D. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature. 2013 May 1. Abstract

Gabuzda D, Yankner BA. Physiology: Inflammation links ageing to the brain. Nature. 2013 May 1. Abstract

 
Comments on News and Primary Papers
  Comment by:  Mark Mattson, ARF Advisor
Submitted 3 May 2013  |  Permalink Posted 3 May 2013

A Hypothalamus-Centric Inflammation-Mediated View of Aging. What About Energy Metabolism?
Zhang et al. (1) report three remarkable findings that transcend the fields of aging, neuroscience, and immunology. First, by selectively manipulating the activation state of the transcription factor NF-κB in cells of the mediobasal hypothalamus (MBH), they show that the lifespan of mice can be extended by reducing NF-κB activity and shortened by elevating NF-κB activity. Second, they provide evidence that a local microglia-mediated inflammatory process in the MBH drives aging of mice. Third, their data suggest that a local inflammation-mediated reduction in gonadotropin-releasing hormone (GnRH) is an important determinant of lifespan. As indicated in the title of their article, the authors’ overall conclusion from their findings is that inflammation-related processes in the hypothalamus program or coordinate the aging process throughout the entire animal. The notion that aging is a "programmed" process has been the subject of much debate in the aging field during the past...  Read more

  Primary Papers: Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH.

Comment by:  Michael T. Heneka
Submitted 13 May 2013  |  Permalink Posted 13 May 2013

Zhang and colleagues conducted experiments to prove a connection among hypothalamic function, innate immune activation, and systemic aging. In their experiments, they assessed systemic aging by overall lifespan, muscle endurance, muscle size, bone mass, tail tendon collagen crosslinking, and dermal thickness. While activation of NF-κB in hypothalamic neurons by IκB kinase-β (IκK-β) reduced lifespan and accelerated signs of systemic aging, delivery of IkKB-α, which inhibits the NF-κB signaling pathway, showed a protective effect. An increasing number of microglial cells expressing tumor necrosis factor α was found in the hypothalamus of aging mice. The authors, however, leave open which aging-dependent stimulus is responsible for this obviously sterile type of innate immune activation. Instead, they suggested that microglial TNF-α accounts for the activation of NF-κB in neighboring hypothalamic neurons. However, this is far from being proven, since inflammatory microglia usually generate other inflammatory mediators, including interleukin-1β and nitric oxide synthase (Wynn et al.,...  Read more
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad